Seek accelerated approval for tilsotolimod
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 13 Jan 2021
- Due
- 31 Mar 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Accelerated Approval would be sought based on the totality of the topline data available in late Q1 2021”
What we found
Evidence strength A What the grades mean
The company announced in April 2021 that the ILLUMINATE-301 trial did not meet its primary endpoint, leading to the discontinuation of the trial and the abandonment of the accelerated approval plan.
-
A Idera Pharmaceuticals, Inc. 10-Q filed 2021-08-09
“In April 2021, following the announcement that ILLUMINATE-301 did not meet its primary endpoint of ORR, we decided to implement a reduction in force” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- Seek
- Deliverable
- Accelerated approval application
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: based on the totality of the topline data
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Idera Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C861838-021978 · Corrections policy